The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Joseph J. Eron(University of North Carolina at Chapel Hill), Patrick Yéni(Hôpital Bichat-Claude-Bernard), Joseph Gathe, Vicente Estrada(Hospital Clínico San Carlos), Edwin DeJesus(Orlando Immunology Center), Schlomo Staszewski(Goethe University Frankfurt), Philip Lackey, Christine Katlama(Sorbonne Université), Benjamin Young(Rose Medical Center), Linda Yau(Research Triangle Park Foundation), Denise Sutherland‐Phillips(GlaxoSmithKline (United States)), Paul Wannamaker(GlaxoSmithKline (United States)), Cindy Vavro(GlaxoSmithKline (United States)), Lisa Patel(GlaxoSmithKline (United States)), Jane Yeo(GlaxoSmithKline (United Kingdom)), Mark S. Shaefer(GlaxoSmithKline (United States))
Cited by 342
Abstract
Related Papers
No related papers found
Powered by citation graph analysis